Dr. Prasad Devarajan is a pediatric nephrologist at the Cincinnati Children’s Hospital Medical Center. He specializes in pediatric acute kidney injury and kidney stone disease. He has authored more than 350 peer-reviewed publications, 100 book chapters, and delivered more than 250 invited lectures nationally and internationally. Dr. Devarajan has been listed in Thomson Reuters’ “World’s Most Influential Scientific Minds” in recognition of ranking among the top 1% of researchers for most cited publications in the entire field of medicine.
Dr. Devarajan will introduce an FDA-approved therapy for patients with Primary Hyperoxaluria Type 1 (PH1) that can help address the underlying cause of the disease. PH1 is a rare, autosomal recessive genetic disorder that leads to kidney stones and progressive kidney damage. It is caused by a genetic mutation that results in the excessive production of oxalate by the liver. Attend this session to learn more about PH1 and a treatment option that can help address the overproduction of oxalate.
Click to register. Registration is required to receive the link for the program. This is a promotional education presentation sponsored by Novo Nordisk; it will not be certified for continuing medical education credit. The faculty will be compensated for their participation in this program. Program contains product-related information.
CLB Member, Novo Nordisk
